Some peptide-based medications are established therapies. Others remain investigational or are not currently available for routine compounding. We evaluate each one individually.
Patients encounter peptide therapies through social media, fitness communities, longevity clinics, and direct-to-consumer vendors. Products sharing the label “peptide” can have completely different evidence, regulatory status, manufacturing requirements, and safety profiles.
Some peptide-based drugs are FDA-approved for specific indications. Others are investigational or remain under regulatory review.
Interest in a substance does not make it eligible for routine pharmacy compounding. Applicable federal and state requirements matter.
Human clinical evidence may range from substantial to limited or preclinical. Popularity is not a substitute for reliable patient data.
Route of administration, dose, source quality, interactions, and patient-specific risk all change the clinical picture.
Empower Med does not assume a therapy is appropriate because it is new, popular, or commercially available. Dr. Everson considers lawful availability, quality of human evidence, known and uncertain risks, pharmacy sourcing, and whether established therapies offer a better-supported option.
A physician consultation can help you understand an emerging therapy, but it does not guarantee that a particular medication, peptide, or compound will be prescribed.
“New and popular are not clinical indications.”
Empower Med separates established peptide-based medications from compounds that remain investigational, restricted, or under regulatory review.
Some prescription medications are peptides or peptide analogs with FDA-approved indications. They are evaluated according to their individual labeling, evidence, risks, and the patient’s clinical needs. Approval of one peptide medication does not establish the safety or legality of another.
These compounds have attracted interest in recovery and longevity settings and have been considered in the federal compounding review process. That process is not the same as FDA drug approval and does not make them routinely available for clinical compounding.
Empower Med status: Not currently offered.
Evidence, safety information, and regulatory status vary substantially. These compounds are not treated as interchangeable with FDA-approved medications acting on related pathways.
Empower Med status: Not currently offered.
Investigational drugs should not be confused with FDA-approved treatments. Empower Med does not prescribe or facilitate investigational drug candidates simply because they are discussed online or in clinical research.
Empower Med status: Not currently offered unless and until lawfully available and independently determined appropriate.
Before an emerging therapy could become part of Empower Med clinical care, Dr. Everson evaluates its regulatory status, human evidence, safety information, source quality, potential interactions, and whether an established alternative is better supported.
If a therapy is not currently lawful or clinically supportable, the appropriate medical answer may simply be not to prescribe it.
BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, injectable GHK-Cu, retatrutide, cagrilintide, and similar emerging compounds are not currently offered by Empower Med.
We continue to monitor FDA action, applicable compounding requirements, and the developing clinical evidence. If future regulatory action makes a therapy lawfully available, Empower Med will independently evaluate its evidence, safety profile, sourcing requirements, and clinical role before deciding whether to offer it.
Questions about an emerging therapy?
Bring the name of the medication or compound to your physician consultation. Dr. Everson can help you understand its regulatory status, evidence, potential risks, and established alternatives.
Request a Physician ConsultationA consultation does not guarantee that any particular medication or therapy will be prescribed.
